Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice

Cancers

Volumn 2, Issue 4, 2010, Pages 2153-2170

  Stabile, Laura P ^a,b   Rothstein, Mary E ^a   Keohavong, Phouthone ^b   Lenzner, Diana ^c   Land, Stephanie R ^b,c   Gaither Davis, Autumn L ^a,b   Kim, K Jin ^d   Kaminski, Naftali ^a,b   Siegfried, Jill M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Galaxy Biotech LLC   (United States)

Author keywords

c Met; EGFR; HGF; Lung cancer

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY L2G7; PLACEBO; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AGED; AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MONOTHERAPY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TOBACCO; TRANSGENIC MOUSE;

EID: 79952272155     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2042153     Document Type: Article

References (30)

1. Tsao, M.S.; Liu, N.; Chen, J.R.; Pappas, J.; Ho, J.; To, C.; Viallet, J.; Park, M.; Zhu, H. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998, 20, 1-16.
2. Selvaggi, G.; Novello, S.; Torri, V.; Leonardo, E.; De Giuli, P.; Borasio, P.; Mossetti, C.; Ardissone, F.; Lausi, P.; Scagliotti, G.V. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann. Oncol. 2004, 15, 28-32.
3. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haseriat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
4. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lineman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fuji, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
5. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2, e73.
6. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043.
7. Cipriani, N.A.; Abidoye, O.O.; Vokes, E.; Salgia, R. MET as a target for treatment of chest tumors. Lung Cancer 2009, 63, 169-179.
8. Stabile, L.P.; Lyker, J.S.; Land, S.R.; Dacic, S.; Zamboni, B.A.; Siegfried, J.M. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006, 27, 1547-1555.
9. Stabile, L.P.; Rothstein, M.E.; Keohavong, P.; Jin, J.; Yin, J.; Land, S.R.; Dacic, S.; Luong, T.M.; Kin, K.J.; Dulak, A.M.; Siegfried, J.M. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol. Cancer Ther. 2008, 7, 1913-1922.
10. Siegfried, J.M.; Gubish, C.T.; Rothstein, M.E.; Queiroz de Oliveira, P.E.; Stabile, L.P. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol. Pharmacol. 2007, 72, 769-779.
11. Dulak, A.M.; Siegfried, J.M. The Src family kinases mediate EGFR-induced prolonged c-Met phosphorylation in non-small cell lung cancer. American Association for Cancer Research Annual Meeting: Proceedings 2009, Denver, CO, USA, 18-22 April 2009; ACCR: Philadelphia, PA, USA, 2009.
12. Puri, N.; Salgia, R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in nonsmall cell lung cancer. J. Carcinog. 2008, 7, 9.
13. Siegfried, J.M.; Krishnamachary, N.; Gaither Davis, A.; Gubish, C.; Hunt, J.D.; Shriver, S.P. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm. Pharmacol. Ther. 1999, 12, 291-302.
14. Wilson, D.O.; Weissfeld, J.L.; Fuhrman, C.R.; Fisher, S.N.; Balogh, P.; Landreneau, R.J.; Luketich, J.D.; Siegfried, J.M. The Pittsburgh Lung Screening Study (PLuSS): Outcomes within 3 years of a first computed tomography scan. Am. J. Respir. Crit. Care Med. 2008, 178, 956-961.
15. Siegfried, J.M.; Luketich, J.D.; Stabile, L.P.; Christie, N.; Land, S.R. Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. Chest 2004, 125, 116S-119S.
16. Stabile, L.P.; Lyker, J.S.; Gubish, C.T.; Zhang, W.; Grandis, J.R.; Siegfried, J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005, 65, 1459-1470.
17. Guo, A.; Villen, J.; Kornhauser, J.; Lee, K.A.; Stokes, M.P.; Rikova, K.; Possemato, A.; Nardone, J.; Innocenti, G.; Wetzel, R.; Wang, Y.; MacNeil, J.; Mitchell, J.; Gygi, S.P.; Rush, J.; Polakiewicz, R.D.; Comb, M.J. Signaling networks assembled by oncogenic EGFR and c- Met. Proc. Natl. Acad. Sci. USA 2008, 105, 692-697.
18. Hammond, D.E.; Hyde, R.; Kratchmarova, I.; Beynon, R.J.; Blagoev, B.; Clague, M.J. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J. Proteome Res. 2010, 9, 2734-2742.
19. Kim, C.H.; Lee, J.S.; Kang, S.O.; Bae, J.H.; Hong, S.P.; Kahng, H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol. 2007, 43, 1021-1025.
20. Kasahara, K.; Arao, T.; Sakai, K.; Matsumoto, K.; Sakai, A.; Kimura, H.; Sone, T.; Horike, A.; Nishio, M.; Ohira, T.; Ikeda, N.; Yamanaka, T.; Saijo, N.; Nishio, K. Impact of serum HGF on treatment response to EGFR tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin. Can. Res. 2010, 16, 4616-4624.
21. Ishikawa, N.; Daigo, Y.; Takano, A.; Taniwaki, M.; Kato, T.; Hayama, S.; Murakami, H.; Takeshima, Y.; Inai, K.; Nishimura, H.; Tsuchiya, E.; Kohno, N.; Nakamura, Y. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005, 65, 9176-9184.
22. Busser, B.; Sancey, L.; Josserand, V.; Niang, C.; Favrot, M.C.; Coll, J.L.; Hurbin, A. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small cell lung cancers. Mol. Therapy 2010, 18, 528-535.
23. Chang, M.H.; Ahn, H.K.; Lee, J.; Jung, C.K.; Choi, Y.L.; Park, Y.H.; Ahn, J.S.; Park, K.; Ahn, M.J. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors. Cancer 2010, doi: 10.1002/cncr.25560.
24. Kawaguchi, K.; Murakami, H.; Taniguchi, T.; Fujii, M.; Kawata, S.; Fukui, T.; Kondo, Y.; Osada, H.; Usami, N.; Yokoi, K.; Ueda, Y.; Yatabe, Y.; Ito, M.; Hida, T.; Sekido, Y. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009, 30, 1097-1105.
25. Seiwert, T.Y.; Jagadeeswaran, R.; Faoro, L.; Janamanchi, V.; Nallasura, V.; El Dinali, M.; Yala, S.; Kanteti, R.; Cohen, E.E.; Lingen, M.W.; Martin, L.; Krishnaswany, S.; Klein-Szanto, A.; Christensen, J.G.; Vokes, E.E.; Salgia, R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009, 69, 3021-3031.
26. Lal, B.; Goodwin, C.R.; Sang, Y.; Foss, C.A.; Cornet, K.; Muzamil, S.; Pomper, M.G.; Kim, J.; Laterra, J. EGFRvIII and c-Met pathway inhibitors synergize against PTENnull/ EGFRvIII+ glioblastoma xenografts. Mol. Cancer. Ther. 2009, 8, 1751-1760.
27. Zhang, Y.W.; Staal, B.; Essenburg, C.; Su, Y.; Kang, L.; West, R.; Kaufman, D.; Dekoning, T.; Eagleson, B.; Buchanan, S.G.; Vande Woude, G.F. MET kinase inhibitor SGX523 synergizes with epidermal growth factor inhibitor erlotinib in a hepatocyte growth factordependent fashion to suppress carcinoma growth. Cancer Res. 2010, 70, 6880-6890.
28. Schiller, J.H.; Akerley, W.L.; Brugger, W.; Ferrari, D.; Garmey, E.G.; Gerber, D.E.; Orlov, S.V.; Ramlau, R.; Von Pawel, J.; Sequist, L.V. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 vs. erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2010, 28, 18s Abstract LBA7502.
29. Riely, G.J.; Marks, J.; Pao, W. KRAS mutations in non-small cell lung cancer. Proc Amer. Thorac. Soc. 2009, 6, 201-205.
30. Fan, S.; Meng, Q.; Laterra, J.J.; Rosen, E.M. Ras effector pathways modulate scatter factorstimulated NF-kB signaling and protection against DNA damage. Oncogene 2007, 26, 4774-4796.